Neurology

Ono Pharmaceutical joins forces with Aitia for drug discovery in neurology

Japan-based Ono Pharmaceutical has signed an agreement with US biotechnology company Aitia to collaborate on drug discovery in neurological diseases.

FDA grants rare paediatric designation to Vanda’s CMT2S therapy

The US Food and Drug Administration (FDA) has granted rare paediatric disease designation to Vanda Pharmaceuticals’ VCA-894A, an investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S).

Otsuka agrees to acquire Transcend Therapeutics for $1.22bn

Otsuka Pharmaceutical has signed an agreement to fully acquire Transcend Therapeutics through its subsidiary Otsuka America for a potential consideration of $1.225bn.

Eisai and Biogen report Leqembi’s MHRA approval for Alzheimer’s

Eisai and Biogen have announced the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) approval for Leqembi (lecanemab) for intravenous (IV) maintenance dosing once every four weeks to treat early Alzheimer’s disease.

Nilo Therapeutics raises $101m to develop neural circuit therapies

Nilo Therapeutics has been launched with $101m series A funding, led by The Column Group (TCG), DCVC Bio, and Lux Capital, with additional participation from the Gates Foundation and Alexandria Venture Investments.

AbbVie files NDA with FDA for tavapadon to treat Parkinson’s disease

AbbVie has filed a New Drug Application with the US Food and Drug Administration (FDA) for tavapadon, a selective dopamine D1/D5 receptor partial agonist that has been investigated as a once-daily oral treatment for Parkinson's disease.

Lilly secures EC approval for Kisunla to treat Alzheimer’s disease

Eli Lilly and Company (Lilly) has received the European Commission (EC) marketing authorisation for Kisunla (donanemab) to treat early symptomatic Alzheimer's disease in adults with mild cognitive impairment or mild dementia.

Leqembi approved in Australia to treat early Alzheimer’s

Swedish biopharma company BioArctic announced that Australia’s Therapeutic Goods Administration (TGA) has approved Leqembi (lecanemab) to treat early Alzheimer's disease in adults.

FDA grants breakthrough therapy status to Ionis ION582 to treat Angelman syndrome

Ionis Pharmaceuticals has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for ION582, an investigational antisense medicine designed to treat Angelman syndrome (AS).